Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market
Ocugen and Bharat Biotech to share US commercialization profits
Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US
COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients
COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.